ATE399210T1 - Knockout-mutante von vaccinia-virus und verwendung davon - Google Patents
Knockout-mutante von vaccinia-virus und verwendung davonInfo
- Publication number
- ATE399210T1 ATE399210T1 AT02772289T AT02772289T ATE399210T1 AT E399210 T1 ATE399210 T1 AT E399210T1 AT 02772289 T AT02772289 T AT 02772289T AT 02772289 T AT02772289 T AT 02772289T AT E399210 T1 ATE399210 T1 AT E399210T1
- Authority
- AT
- Austria
- Prior art keywords
- mva
- viruses
- mutant
- vaccinia virus
- present
- Prior art date
Links
- 241000700618 Vaccinia virus Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
- C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10144664A DE10144664B4 (de) | 2001-09-11 | 2001-09-11 | Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE399210T1 true ATE399210T1 (de) | 2008-07-15 |
Family
ID=7698583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02772289T ATE399210T1 (de) | 2001-09-11 | 2002-09-11 | Knockout-mutante von vaccinia-virus und verwendung davon |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7049145B2 (de) |
| EP (1) | EP1425404B1 (de) |
| JP (1) | JP4406561B2 (de) |
| AT (1) | ATE399210T1 (de) |
| AU (1) | AU2002337083A1 (de) |
| CA (1) | CA2459754C (de) |
| DE (2) | DE10144664B4 (de) |
| DK (1) | DK1425404T3 (de) |
| WO (1) | WO2003023040A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
| WO2005028634A2 (en) * | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| JP4606838B2 (ja) * | 2004-10-20 | 2011-01-05 | 富士フイルム株式会社 | 電子内視鏡装置 |
| US20090060947A1 (en) * | 2006-05-19 | 2009-03-05 | Sanofi Pasteur, Inc. | Immunological compositions |
| WO2010127115A1 (en) | 2009-04-30 | 2010-11-04 | Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) | Modified immunization vectors |
| RU2505606C2 (ru) | 2010-10-14 | 2014-01-27 | Адзиномото Ко., Инк. | Способ получения монатина |
| FR2969497B1 (fr) * | 2010-12-27 | 2013-06-28 | Ceva Sante Animale | Composition luminescente comme biomarqueur dans un oeuf aviaire, dispositif et procede correspondants. |
| JP6569209B2 (ja) * | 2014-01-07 | 2019-09-04 | ソニー株式会社 | 電気的測定用カートリッジ、並びに電気的測定装置及び電気的測定方法 |
| CN107735103B (zh) | 2015-02-25 | 2022-05-27 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的非复制型的修饰的痘苗病毒安卡拉(mva)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合 |
| CN116173193A (zh) | 2015-04-17 | 2023-05-30 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| WO2017147553A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| JP7034080B2 (ja) * | 2016-02-25 | 2022-03-11 | メモリアル スローン ケタリング キャンサー センター | ヒトｆｌｔ３ｌを発現する組換えｍｖａまたはｍｖａδｅ３ｌおよび固形腫瘍に対する免疫療法薬としてのそれらの使用 |
| US10842835B2 (en) | 2016-05-25 | 2020-11-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic vaccinia virus mutants and using same for cancer treatment |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| WO2021260065A1 (en) | 2020-06-24 | 2021-12-30 | Consejo Superior De Investigaciones Científicas (Csic) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| EP3928789A1 (de) | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-basierter impfstoff gegen covid-19 exprimierende sars-cov-2-antigene |
| WO2022269003A1 (en) | 2021-06-23 | 2022-12-29 | Consejo Superior De Investigaciones Cientificas | MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN |
| EP4108257A1 (de) | 2021-06-23 | 2022-12-28 | Consejo Superior De Investigaciones Científicas | Impfstoff auf mva-basis gegen covid-19, der ein präfusionsstabilisiertes sars-cov-2-s-protein exprimiert |
| EP4316514A1 (de) | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Vektoren auf mva-basis und ihre verwendung als impfstoff gegen sars-cov-2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6287570B1 (en) * | 1998-11-23 | 2001-09-11 | Patricia L. Foley | Vaccine against swine influenza virus |
| WO2000073487A1 (en) * | 1999-05-27 | 2000-12-07 | Arizona Board Of Regents | Novel viral vectors having enhanced effectiveness with dramatically reduced virulence |
| KR101172997B1 (ko) | 2005-09-22 | 2012-08-09 | 도쿄엘렉트론가부시키가이샤 | 플라즈마 처리 장치 |
-
2001
- 2001-09-11 DE DE10144664A patent/DE10144664B4/de not_active Expired - Fee Related
-
2002
- 2002-09-11 AT AT02772289T patent/ATE399210T1/de active
- 2002-09-11 DE DE60227268T patent/DE60227268D1/de not_active Expired - Lifetime
- 2002-09-11 JP JP2003527104A patent/JP4406561B2/ja not_active Expired - Fee Related
- 2002-09-11 EP EP02772289A patent/EP1425404B1/de not_active Expired - Lifetime
- 2002-09-11 DK DK02772289T patent/DK1425404T3/da active
- 2002-09-11 WO PCT/EP2002/010199 patent/WO2003023040A2/en active IP Right Grant
- 2002-09-11 US US10/488,987 patent/US7049145B2/en not_active Expired - Fee Related
- 2002-09-11 CA CA2459754A patent/CA2459754C/en not_active Expired - Fee Related
- 2002-09-11 AU AU2002337083A patent/AU2002337083A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002337083A1 (en) | 2003-03-24 |
| EP1425404A2 (de) | 2004-06-09 |
| CA2459754C (en) | 2011-05-10 |
| EP1425404B1 (de) | 2008-06-25 |
| US7049145B2 (en) | 2006-05-23 |
| DK1425404T3 (da) | 2008-10-06 |
| US20050028226A1 (en) | 2005-02-03 |
| DE60227268D1 (de) | 2008-08-07 |
| JP4406561B2 (ja) | 2010-01-27 |
| WO2003023040A2 (en) | 2003-03-20 |
| CA2459754A1 (en) | 2003-03-20 |
| WO2003023040A3 (en) | 2003-11-27 |
| DE10144664B4 (de) | 2005-06-09 |
| JP2005502360A (ja) | 2005-01-27 |
| DE10144664A1 (de) | 2003-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60227268D1 (de) | Knockout-mutante von vaccinia-virus und verwendung davon | |
| MX342639B (es) | Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica. | |
| BRPI0309631A8 (pt) | vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4 | |
| DE69737886D1 (de) | Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays | |
| DK0702085T3 (da) | Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus | |
| DE122011100037I1 (de) | Rekombinante influenzaviren zur vakzinherstellung und gentherapie. | |
| HK1076835A1 (en) | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter | |
| DE60224843D1 (de) | Herstellung von viren, virusisolaten, und impfstoffen | |
| NO20062948L (no) | Promotere for ekspresjon i modifisert vaccinia-virus Ankara | |
| UA82998C2 (ru) | Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті | |
| ATE352557T1 (de) | Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff | |
| DE60336653D1 (de) | Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren | |
| DK0831899T3 (da) | Rekombinant koppevirus-calicivirus-præparater og anvendelser | |
| ATE453708T1 (de) | Impfstoff gegen west nile virus | |
| ATE428725T1 (de) | Neurovirulenter stamm des west-nile-virus und anwendungen davon | |
| HUP0103871A2 (hu) | Rekombináns CELO-vírus és CELO vírus DNS | |
| WO2004035808A3 (en) | Method for detecting viral inactivating agents | |
| SE0002498D0 (sv) | Papillomavirus vaccine | |
| MY146370A (en) | Classical swine fever tissue culture live vaccine virus, the tissue culture method of the same and classical swine fever tissue culture live vaccine comprising the same | |
| WO2002078621A3 (en) | Replication-competent recombinant virus and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1425404 Country of ref document: EP |